Dynavax Technologies Corporation (NASDAQ: DVAX) is off to an incredibly strong start in the pre-market this morning, and for good reason. The company announced the results of the FDA advisory committee meeting surrounding Heplisav-B, and those results proved to be positive. Of course, this led to excitement among investors who are sending the stock toward the top. As is normally the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:29), DVAX is trading at $17.05 per share after a gain of $7.80 per share or 84.32% thus far today.
DVAX Announces Positive FDA News
As mentioned above, Dynavax Technologies is having an incredibly strong day after investors received some positive news surrounding the FDA Advisory Committee meeting that was focused on Heplisav-B. The committee has voted in favor of approving the treatment. The vote count was an overwhelming 12 to 1.
During the meeting, the advisory committee offered feedback with regard to the design of the DVAX proposed post-marketing pharmocovigilance plan for Helpisav-B, which proved to be positive. As a result, the company believes that it is on track to launch the vaccine commercially in the United States in early 2018. The company also said that if the FDA does approve the vaccine, they will seek recommendations from the CDC advisory committee on immunization practices.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will be keeping a close eye on DVAX. In particular, we’re interested in following the news surrounding Heplisav-B. Following the positive vote from the FDA advisory committee, this vaccine has a strong chance of approval. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!